HSBC upgraded shares of DiaSorin (OTCMKTS:DSRLF – Get Rating) from a hold rating to a buy rating in a research report released on Tuesday morning, The Fly reports.
Several other research analysts also recently commented on DSRLF. Stifel Nicolaus assumed coverage on shares of DiaSorin in a research report on Tuesday, November 29th. They set a hold rating for the company. Berenberg Bank reduced their price objective on shares of DiaSorin from €170.00 ($180.85) to €153.00 ($162.77) in a research note on Tuesday, November 8th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of Hold and a consensus target price of $143.00.
DiaSorin Stock Performance
Shares of DSRLF opened at $132.90 on Tuesday. DiaSorin has a one year low of $107.00 and a one year high of $175.20. The firm has a 50 day simple moving average of $133.52 and a two-hundred day simple moving average of $128.94.
DiaSorin SpA engages in developing, producing and marketing reagent kits for laboratory diagnostics. The firm specializes in the immunodiagnostics and molecular diagnostics segments. It provides clinical services in the areas like Infectious Diseases, Bone and Mineral, Endocrinology, Hypertension, Oncology, Stool Diagnostics and Autoimmunity.
- Get a free copy of the StockNews.com research report on DiaSorin (DSRLF)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Receive News & Ratings for DiaSorin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaSorin and related companies with MarketBeat.com's FREE daily email newsletter.